Nuclear factor kappa B in the treatment of inflammatory and tumor diseases;Nukleární faktor kappa B v léčbě zánětlivých a nádorových onemocně ní

Casopis Lekaru Ceskych

Volumn 143, Issue 10, 2004, Pages 680-684

  Leníček, Martin ^a   Muchova L ^a   Vitek L ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Apoptosis; Inflammation; Nuclear factor kappa B; Therapy; Tumorigenesis; Tumors

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

APOPTOSIS; CARCINOGENESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MODULATION; NONHUMAN; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; THERAPY; TUMOR;

APOPTOSIS; HUMANS; INFLAMMATION; NEOPLASMS; NF-KAPPA B;

EID: 7644225607     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Sen, R., Baltimore, D.: Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell, 1986, 46, s. 705-716.
2. Karin, M., Cao, Y., Greten, F. R., Li, Z. W.: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer, 2002, 2, s. 301-310.
3. Ghosh, S., May, M. J., Kopp, E. B.: NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev. Immunol., 1998, 16, s. 225-260.
4. Epinat, J. C., Gilmore, T. D.: Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway. Oncogene, 1999, 18, s. 6896-6909.
5. Barnes, P. J., Karin, M.: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases, N. Engl. J. Med., 1997, 336, s, 1066-1071,
6. Bressler, P., Brown, K., Timmer, W. et al.: Mutational analysis of the p50 subunit of NF-kappa B and inhibition of NF-kappa B activity by trans-dominant p50 mutants. J. Virol., 1993, 67, s. 288-293.
7. Baeuerle, P. A., Baltimore, D.: NF-kappa B: ten years after. Cell, 1996, 87, s. 13-20.
8. Dechend, R., Hirano, F., Lehmann, K. et al.: The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators. Oncogene, 1999, 18, s. 3316-3323.
9. Bundy, D. L., McKeithan, T. W.: Diverse Effects of BCL3 Phosphorylation on Its Modulation of NF-kappa B p52 Homodimer Binding to DNA. J. Biol. Chem., 1997, 272, s. 33132-33139.
10. Jouanolle, A. M., Bouabin, G., Halimi, C. et al.: Novel mutation in ferroportin 1 gene is associated with autosomal dominant iron overload. J. Hepatol., 2003, 39, s. 286-289.
11. Chen, L.W., Egan, L., Li, Z. W. et al.: The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat. Med., 2003, 9, s. 575-581.
12. Grimm, S., Bauer, M. K., Baeuerle, P. A., Schulze, O.: Bcl-2 down-regulates the activity of transcription factor NF-kappaB induced upon apoptosis. J. Cell Biol., 1996, 134, s. 13-23.
13. Beg, A. A., Baltimore, D.: An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science, 1996, 274, s. 782-784.
14. Wang, Y., Cui, H., Schroering, A. et al.: NF-kappa B2 p100 is a pro-apoptotic protein with anti-oncogenic function. Nat. Cell Biol., 2002, 4, s. 888-893.
15. Savill, J.: Apoptosis in resolution of inflammation. J. Leukoc. Biol., 1997, 61, s. 375-380.
16. Savill, J., Haslett, C.: Granulocyte clearance by apoptosis in the resolution of inflammation. Semin. Cell Biol., 1995, 6, s. 385-393.
17. Wang, C. Y., Mayo, M. W., Baldwin, A. S., Jr.: TNF- and Cancer Therapy-Induced Apoptosis : Potentiation by Inhibition of NF-kappa B. Science, 1996, 274, s. 784-787.
18. Van Antwerp, D. J., Martin, S. J., Kafri, T. et al.: Suppression of TNF-alpha -Induced Apoptosis by NF-kappa B. Science, 1996, 274, s. 787-789.
19. Fujisawa, K., Aono, H., Hasunuma, T. et al.: Activation of transcription factor NF-kappa B in human synovial cells in response to tumor necrosis factor alpha. Arthritis Rheum, 1996, 39, s. 197-203.
20. Neurath, M. F., Pettersson, S., Meyer, Z., Strober, W.: Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat. Med., 1996, 2, s. 998-1004.
21. Rogler, G., Brand, K., Vogl, D. et al.: Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology, 1998, 115, s. 357-369.
22. Sovak, M. A., Bellas, R. E., Kim, D. W. et al.: Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest., 1997, 100, s. 2952-2960.
23. Hardwick, J. C., Van, D., Offerhaus, G. J. et al.: NF-kappaB, p38 MAPK and INK are highly expressed and active in the stroma of human colonic adenomatous polyps. Oncogene, 2001, 20, s. 819-827.
24. Bargou, R. C., Leng, C., Krappmann, D. et al.: High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood, 1996, 87, s. 4340-4347.
25. Visconti, R., Cerutti, J., Battista, S. et al.: Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene, 1997, 15, s. 1987-1994.
26. Shattuck, B., Richmond, A.: Enhanced degradation of I-kappaB alpha contributes to endogenous activation of NF-kappaB in Hs294T melanoma cells. Cancer Res., 1997, 57, s. 3032-3039.
27. Wang, W., Abbruzzese, J. L., Evans, D. B. et al.: The Nuclear Factor-{ {kappa} }B RelA Transcription Factor Is Constitutevely Activated in Human Pancreatic Adenocarcinoma Cells. Clin. Cancer Res., 1999, 5, s. 119-127.
28. Wong, B. C., Jiang, X., Fan, X. M. et al.: Suppression of RelA/p65 nuclear translocation independent of IkappaB-alpha degradation by cyclooxygenase-2 inhibitor in gastric cancer. Oncogene, 2003, 22, s. 1189-1197.
29. Kawamura, I., Morishita, R., Tsujimoto, S. et al.: Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice. Gene Ther., 2001, 8, s. 905-912.
30. Biggins, K. A., Ferez, J. R., Coleman, T. A. et al.: Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression. Proc. Natl. Acad. Sci. USA, 1993, 90, s. 9901-9905.
31. Richardson, P. G., Hideshima, T., Anderson, K. C.: Bortezomib (PS-341): A Novel, First-in-Class Proteasome Inhibitor for the Treatment of Multiple Myeloma and Other Cancers. Cancer Control, 2003, 10, s. 361-369.
32. Waddick, K. G., Uckun, F. M.: Innovative treatment programs against cancer: II. nuclear factor-[kappa]B (NF-[kappa]B) as a molecular target. Biochemical Pharmacology, 1999, 57, s. 9-17.
33. Tsai, S. H., Liang, Y. C., Lin, S., Lin, J. K.: Suppression of TNFalpha-mediated NFkappaB activity by myricetin and other flavonoids through downregulating the activity of IKK in ECV304 cells. J. Cell Biochem., 1999, 74, s. 606-615.
34. Liang, M. C., Bardhan, S., Li, C. et al.: Jesterone dimer, a synthetic derivative of the fungal metabolite jesterone, blocks activation of transcription factor nuclear factor kappaB by inhibiting the inhibitor of kappaB kinase. Mol. Pharmacol., 2003, 64, s. 123-131.
35. Yin, M. J., Yamamoto, Y., Gaynor, R.B.: The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinasebeta. Nature, 1998, 396, s. 77-80.
36. Kopp, E., Ghosh, S.: Inhibition of NF-kappa B by sodium salicylate and aspirin. Science, 1994, 265, s. 956-959.
37. Castro, A. C., Dang, L. C., Soucy, F. et al.: Novel IKK inhibitors: beta-carbolines. Bioorg. Med. Chem. Lett., 2003, 13, s. 2419-2422.
38. Kohori, M., Yang, Z., Gong, D. et al.: Wedelolactone suppresses LPS-induced caspase-11 expression'by directly inhibiting the IKK complex. Cell Death. Differ., 2004, 11, s. 123-130.
39. Kishore, N., Sommers, C., Mathialagan, S. et al.: A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts. J. Biol. Chem., 2003, 278, s. 32861-32871.
40. Katsuyama, K., Shichiri, M., Marumo, F., Hirata, Y.: NO Inhibits Cytokine-Induced iNOS Expression and NF-{kappa}B Activation by Interfering With Phosphorylation and Degradation of I {kappa} B-{alpha}. Arterioscler. Thromb. Vasc. Biol., 1998; 18, s. 1796-1802.
41. Lind, D. S., Hochwald, S. N., Malaty, J. et al.: Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery, 2001, 130, s. 363-369.
42. Frantz, B., Nordby, E. C., Bren, G. et al.: Calcineurin acts in synergy with PMA to inactivate I kappa B/MAD3, an inhibitor of NF-kappa B. EMBO J, 1994, 13, s. 861-870.
43. Rao, S., Porter, D. C., Chen, X. et al.: Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc. Natl. Acad. Sci. USA, 1999, 96, s. 7797 až 7802.
44. Acquisto, F., Sautebin, L., Iuvone, T. et al.: Prostaglandins prevent inducible nitric oxide synthase protein expression by inhibiting nuclear factor-kappaB activation in J774 macrophages. FEBS Lett, 1998, 440, s. 76-80.
45. Higuchi, M., Singh, S., Chan, H., Aggarwal, B. B.: Protease inhibitors differentially regulate tumor necrosis factor-induced apoptosis, nuclear factor-kappa B activation, cytotoxicity, and differentiation. Blood, 1995, 86, s. 2248-2256.
46. Pahl, H. L., Krauss, B., Schulze, O. et al.: The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kappaB. J. Exp. Med., 1996, 183, s. 1829-1840.
47. Singh, S., Natarajan, K., Aggarwal, B. B.: Capsaicin (8-methyl-N- vanillyl-6-nonenamide) is a potent inhibitor of nuclear transcription factor-kappa B activation by diverse agents. J. Immunol., 1996, 157, s. 4412-4420.
48. Lin, Y. Z., Yao, S., Veach, R. A. et al.: Inhibition of Nuclear Translocation of Transcription Factor NF-[IMAGE]B by a Synthetic Peptide Containing a Cell Membrane-permeable Motif and Nuclear Localization Sequence. J. Biol. Chem., 1995, 270, s. 14255-14258.
49. Schwartz, S. A., Hernandez, A., Mark, E.: The role of NF-kappaB/IkappaB proteins in cancer: implications for novel treatment strategies. Surg. Oncol., 1999, 8, s. 143-153.
50. Matthews, J. R., Botting, C. H., Panico, M. et al.: Inhibition of NF-kappaB DNA binding by nitric oxide. Nucl. Acids. Res., 1996, 24, s. 2236-2242.
51. Auphan, N., DiDonato, J. A., Rosette, C. et al.: Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science, 1995, 270, s. 286-290.
52. Sumitomo, M., Tachibana, M., Ozu, C. et al.: Induction of apoptosis of cytokine-producing bladder cancer cells by adenovirus-mediated IkappaBalpha overexpression. Hum. Gene Ther., 1999, 10, s. 37-47.
53. Brown, K., Gerstberger, S., Carlson, L. et al.: Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science, 1995, 267, s. 1485-1488.
54. Rodriguez, M. S., Thompson, J., Hay, R. T., Dargemont, C.: Nuclear Retention of Ikappa Balpha Protects It from Signal-induced Degradation and Inhibits Nuclear Factor kappa B Transcriptional Activation. J. Biol. Chem., 1999, 274, s. 9108-9115.
55. Jeay, S., Pianetti, S., Kagan, H. M., Sonenshein, G. E.: Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B. Mol. Cell Biol., 2003, 23, s. 2251-2263.
56. Chawla-Sarkar, M., Bauer, J. A., Lupica, J. A. et al.: Suppression of NF-{kappa}B Survival Signaling by Nitrosylcobalamin Sensitizes Neoplasms to the Anti-tumor Effects of Apo2L/TRAIL. J. Biol. Chem., 2003, 278, s. 39461-39469.
57. Yin, W., Yang, J. H., Hu, X. M. et al.: [Effects of polymixin B on I-kappaB kinase mRNA expression in lipopolysaccharide- induced pulmonary alveolar macrophages]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, 2003, 15, s. 429-431.
58. Yang, J. P., Merin, J. P., Nakano, T. et al.: Inhibition of the DNA-binding activity of NF-kappa B by gold compounds in vitro. FEBS Lett, 1995, 361, s. 89-96.
59. Wang, P., Wu, P., Siegel, M. I. et al.: Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J. Biol. Chem., 1995, 270, s. 9558-9563.
60. Segain, J. P., Raingeard, D., Bourreille, A. et al.: Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut, 2000, 47, s. 397-403.
61. Bantel, H., Berg, C., Vieth, M. et al.: Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am. J. Gastroenterol., 2000, 95, s. 3452-3457.
62. Inoue, I., Itoh, F., Aoyagi, S. et al.: Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem. Biophys. Res. Commun., 2002, 290, s. 131-139.